Which PARP inhibitor was recently found to increase quality of life in patients with ovarian cancer? READ MORE

Conferences

British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.

READ MORE

Researchers compared intensity-modulated radiation therapy versus conventional radiation therapy by evaluating acute toxicities in the GI and GU systems.

READ MORE

Prolonging platinum-free interval by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer.

READ MORE

News

Which PARP inhibitor was recently found to increase quality of life in patients with ovarian cancer?

READ MORE

Patients with ovarian cancer who are responsive to platinum-based chemotherapy may experience more than double an increase in PFS with a specific maintenance therapy, regardless of their disease characterization.

READ MORE

Administration of a PARP inhibitor to patients with recurrent ovarian cancer after an initial response to platinum-based chemotherapy helps maintain quality of life during treatment.

READ MORE

Less than 20% of patients with a history of ovarian cancer meeting NCCN guidelines have undergone genetic testing or have discussed testing with their health care providers.

READ MORE

Research in Review

High-grade serous ovarian cancer can be categorized in five molecular subtypes associated with survival and surgical outcomes.

READ MORE

New research questions the value of risk-reducing mastectomy within five years of ovarian cancer diagnosis in patients with BRCA mutations.

READ MORE

A tool for measuring blood flow and volume to ovarian cancer tumors accurately predicts the effectiveness of treatment.

READ MORE

Women with advanced ovarian cancer who express a certain tumor antigen will likely experience a shorter progression-free survival and overall survival than those without the antigen.

READ MORE

Resources

The American College of Obstetricians and Gynecologists has recently updated its clinical guidelines for the management of hereditary breast and ovarian cancer syndrome.

READ MORE

Slideshow

Ovarian cancer is one of the leading causes of cancer death among women in the United States. Our understanding of treatment options, prognostic indicators, and value in ovarian cancer is constantly evolving. Review the latest research breakthroughs involving ovarian cancer therapies, biomarkers, prognoses, surgical outcomes, and personalized treatment.

READ MORE